🧾 What This Document Is

This is an 8-K filing—a current report companies file with the SEC to announce major events that shareholders should know about. Attached to it (as Exhibit 99.1) is LENSAR's official press release with its fourth-quarter and full-year 2025 financial results and a business update.

👉 Why it matters: This report gives investors a snapshot of the company's recent performance and, crucially, signals that LENSAR is now moving forward alone after a major deal fell through.

🏢 What The Company Does

LENSAR is a medical technology company. They don't make drugs or supplements—they make sophisticated laser systems for eye surgery, specifically for cataracts.

👉 In simple terms: Think of them as a company that builds high-tech, robotic lasers that help eye surgeons perform cataract operations more precisely. Their flagship product is the ALLY Robotic Cataract Laser System.

💰 Financial Highlights (Q4 & Full Year 2025)

This is the core of the report. Here’s a breakdown of the key numbers.

Revenue

• Total Q4 Revenue: $16.0 million, down 4% from Q4 2024.
• Full-Year 2025 Revenue: $58.4 million, up 9% from 2024.
• The Big Story: Recurring Revenue. LENSAR makes money from two main sources: one-time system sales and recurring revenue from procedures, leases, and service. The recurring part is their stable, predictable income.
  • Q4 Recurring Revenue: $12.7 million (79% of total revenue).
  • Full-Year 2025 Recurring Revenue: $46.3 million (up 15% from 2024).

Profitability & Cash

• Net Loss (Q4): $1.5 million (or $0.12 per share), a huge improvement from a $18.7 million loss in Q4 2024.
• Cash on Hand (Dec. 31, 2025): $18.0 million, down from $22.5 million a year earlier. They burned through about $4.5 million of cash in 2025.

The Alcon Deal That Wasn't

A massive factor in these results was the terminated merger with Alcon. LENSAR had been planning to be acquired, but the deal was officially called off on March 18, 2026.

• Windfall: LENSAR gets to keep a $10.0 million deposit from Alcon, which will count as income in Q1 2026.
• Costs: They spent $17.1 million in "acquisition-related costs" (legal, advisory fees, etc.) by year-end 2025. About $4.3 million of that will be reversed in Q1 2026 since the deal failed.

🚀 Key Moves & Operational Update

Despite the merger falling apart, the company is highlighting strong operational momentum for its core product.

• ALLY System Growth: They placed 15 ALLY systems in Q4 2025, growing their installed base to ~200 systems—a 48% increase from the end of 2024.
• Backlog: They have 13 ALLY systems sold but not yet installed as of Dec. 31, 2025.
• Total Installed Base: Including older models, their total laser systems in use grew to ~435 (up 13% YoY).
• Procedure Volume: The number of surgeries using their lasers grew 22% for the full year and 20% in Q4. More procedures = more recurring revenue.

📦 Financial Position & Why the Loss Improved

The dramatic reduction in quarterly net loss wasn't primarily from better operations. It was due to accounting for financial instruments.

👉 Key Takeaway: The smaller loss is mainly because the value of "warrant liabilities" (financial obligations tied to their stock price) changed favorably. This is a non-cash accounting adjustment. The Adjusted EBITDA (a measure that strips out these one-time items) was a near-breakeven $0.6 million for the quarter, similar to the prior year.

🔮 What's Next: The Standalone Path

The merger with Alcon is off. CEO Nick Curtis is emphasizing a "renewed commitment" to growing independently.

• Strategy: Focus on expanding market share for the ALLY system and growing the overall market for robotic laser cataract surgery.
• Immediate Impact: The company will record the $10M deposit as income and clean up the related merger costs on its balance sheet in early 2026.
• Conference Call: Management will discuss this new standalone strategy on a call today, March 31, 2026, at 8:30 a.m. ET.

⚖️ The Big Picture

👍 Strengths

• Strong Recurring Revenue Model: 79% of revenue is recurring, creating a predictable income stream.
• Proven Product Adoption: The 48% growth in the ALLY installed base shows strong market acceptance.
• War Chest Boost: Keeping the $10M Alcon deposit significantly boosts their near-term cash position.

⚠️ Risks

• Post-Deal Uncertainty: The company must now execute its standalone plan without the backing and resources of a large partner like Alcon.
• Cash Burn: Despite the deposit, the core business used cash in 2025. Profitability at the net income level remains a challenge.
• One-Time Accounting Gains: The improved quarterly loss is not yet from sustainable operational profit.

🧠 The Analogy

LENSAR's business model is like a high-tech razor-and-blade company. They sell the fancy, expensive robotic laser systems (the "razor") to hospitals and surgery centers. The real, steady money then comes from the ongoing fees for each procedure performed, leases, and service contracts (the "blades").

📇 Key Contacts & People

• Nick Curtis: President and CEO
• Investor Relations: The company's IR section at https://ir.lensar.com is the primary contact point.

🧩 Final Takeaway

LENSAR is reporting solid operational growth for its robotic laser business and a much-improved quarterly loss, but the real story is its abrupt pivot to a standalone strategy after its sale to Alcon collapsed. The unexpected $10 million cash windfall provides a cushion as it attempts to prove it can thrive on its own.